Cargando…

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation

Mesothelioma is a rare cancer of the mesothelial cell layer of the pleura, peritoneum, pericardium and tunica vaginalis. It is typically caused by asbestos, notoriously resistant to chemotherapy and generally considered incurable with a poor life expectancy. Transglutaminase 2 (TG2), a GTP binding r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adhikary, Gautam, Grun, Daniel, Alexander, H. Richard, Friedberg, Joseph S., Xu, Wen, Keillor, Jeffrey W., Kandasamy, Sivaveera, Eckert, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195372/ https://www.ncbi.nlm.nih.gov/pubmed/30349644 http://dx.doi.org/10.18632/oncotarget.26130

Ejemplares similares

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition
por: Fisher, Matthew L., et al.
Publicado: (2015)

ACTL6A suppresses p21(Cip1) expression to enhance the epidermal squamous cell carcinoma phenotype
por: Shrestha, Suruchi, et al.
Publicado: (2020)

Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype
por: Gates, Eric W. J., et al.
Publicado: (2023)

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation
por: Fisher, Matthew L., et al.
Publicado: (2017)

ACTL6A suppresses p21(Cip1) tumor suppressor expression to maintain an aggressive mesothelioma cancer cell phenotype
por: Shrestha, Suruchi, et al.
Publicado: (2021)

Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival
por: Kerr, Candace, et al.
Publicado: (2016)

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
por: Fisher, Matthew L., et al.
Publicado: (2017)

Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif
por: Scharadin, Tiffany M., et al.
Publicado: (2013)

A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
por: Kim, Soo-Youl, et al.
Publicado: (2020)

Using FLIM-FRET to Measure Conformational Changes of Transglutaminase Type 2 in Live Cells
por: Caron, Nicholas S., et al.
Publicado: (2012)

Design of a glutamine substrate tag enabling protein labelling mediated by Bacillus subtilis transglutaminase
por: Oteng-Pabi, Samuel K., et al.
Publicado: (2018)

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia
por: Zonca, Sara, et al.
Publicado: (2017)

Cytosolic Guanine Nucledotide Binding Deficient Form of Transglutaminase 2 (R580a) Potentiates Cell Death in Oxygen Glucose Deprivation
por: Colak, Gozde, et al.
Publicado: (2011)

Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase
por: Gates, Eric W. J., et al.
Publicado: (2023)

Pulmonary transplantation—is it a long-term solution?
por: Kandasamy, Sivaveera, et al.
Publicado: (2023)

Identification of a Population of Epidermal Squamous Cell Carcinoma Cells with Enhanced Potential for Tumor Formation
por: Adhikary, Gautam, et al.
Publicado: (2013)

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort
por: Amin, Waqas, et al.
Publicado: (2019)

Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury
por: Elahi, Anissa, et al.
Publicado: (2021)

Epidermal Transglutaminase (TGase 3) Is Required for Proper Hair Development, but Not the Formation of the Epidermal Barrier
por: John, Susan, et al.
Publicado: (2012)

The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2
por: Bianchi, Nicoletta, et al.
Publicado: (2021)

Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2
por: Jambrovics, Károly, et al.
Publicado: (2020)

AP1 Factor Inactivation in the Suprabasal Epidermis Causes Increased Epidermal Hyperproliferation and Hyperkeratosis but Reduced Carcinogen-Dependent Tumor Formation
por: Rorke, Ellen A., et al.
Publicado: (2010)

Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis
por: Jeong, Eui Man, et al.
Publicado: (2016)

Plasma Membrane Factor XIIIA Transglutaminase Activity Regulates Osteoblast Matrix Secretion and Deposition by Affecting Microtubule Dynamics
por: Al-Jallad, Hadil F., et al.
Publicado: (2011)

MEP50/PRMT5 reduces gene expression by histone arginine methylation and this is reversed by PKCδ/p38δ signaling
por: Saha, Kamalika, et al.
Publicado: (2016)

Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation
por: Jambrovics, Károly, et al.
Publicado: (2019)

Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer
por: Aguiari, Gianluca, et al.
Publicado: (2022)

Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid
por: Qin, Xian-Yang, et al.
Publicado: (2023)

The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells
por: Sullivan, Kelly E., et al.
Publicado: (2017)

Role of Transglutaminase 2 in Cell Death, Survival, and Fibrosis
por: Tatsukawa, Hideki, et al.
Publicado: (2021)

Loss of epidermal AP1 transcription factor function reduces filaggrin level, alters chemokine expression and produces an ichthyosis-related phenotype
por: Young, Christina A, et al.
Publicado: (2017)

Peritoneal mesothelioma
por: Greenbaum, Alissa, et al.
Publicado: (2020)

Primary Peritoneal Desmoplastic Mesothelioma
por: Malla, Sundeep, et al.
Publicado: (2020)

Tissue Transglutaminase Does Not Contribute to the Formation of Mutant Huntingtin Aggregates
por: Chun, Wanjoo, et al.
Publicado: (2001)

Chk1 inhibition as a novel therapeutic strategy in melanoma
por: Hwang, Bor-Jang, et al.
Publicado: (2018)

Exercise, Vascular Stiffness, and Tissue Transglutaminase
por: Steppan, Jochen, et al.
Publicado: (2014)

The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression
por: Tabolacci, Claudio, et al.
Publicado: (2019)

A Multidisciplinary Approach Establishes a Link between Transglutaminase 2 and the Kv10.1 Voltage-Dependent K(+) Channel in Breast Cancer
por: Canella, Rita, et al.
Publicado: (2022)

Suppression of AP1 Transcription Factor Function in Keratinocyte Suppresses Differentiation
por: Han, Bingshe, et al.
Publicado: (2012)

Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives
por: Katt, William P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kcm3o0gcjfmouvgcbbmqdeh9nr